Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target

Non-alcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide, and is closely associated with the increased risk of the prevalence of obesity and diabetes. NAFLD begins with the presence of >5% excessive lipid accumulation in the liver, and potentia...

Full description

Bibliographic Details
Main Author: Hanqing Chen
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2022-12-01
Series:Liver Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2542568422000459
_version_ 1797975195536850944
author Hanqing Chen
author_facet Hanqing Chen
author_sort Hanqing Chen
collection DOAJ
description Non-alcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide, and is closely associated with the increased risk of the prevalence of obesity and diabetes. NAFLD begins with the presence of >5% excessive lipid accumulation in the liver, and potentially develops into non-alcoholic steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma. Therefore, insight into the pathogenesis of NAFLD is of key importance to its effective treatment. Iron is an essential element in the life of all mammalian organisms. However, the free iron deposition is positively associated with histological severity in NAFLD patients due to the production of reactive oxygen species via the Fenton reaction. Recently, several iron metabolism-targeted therapies, such as phlebotomy, iron chelators, nanotherapeutics. and ferroptosis, have shown their potential as a therapeutic option in the treatment of NAFLD and as a clinical strategy to intervene in the progression of NAFLD. Herein, we review the recent overall evidence on iron metabolism and provide the mechanism of hepatic iron overload-induced liver pathologies and the recent advances in iron metabolism-targeted therapeutics in the treatment of NAFLD.
first_indexed 2024-04-11T04:31:39Z
format Article
id doaj.art-9463ff67ac644bab87bb4419fc5318df
institution Directory Open Access Journal
issn 2542-5684
language English
last_indexed 2024-04-11T04:31:39Z
publishDate 2022-12-01
publisher KeAi Communications Co., Ltd.
record_format Article
series Liver Research
spelling doaj.art-9463ff67ac644bab87bb4419fc5318df2022-12-29T04:13:49ZengKeAi Communications Co., Ltd.Liver Research2542-56842022-12-0164203213Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic targetHanqing Chen0Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou Key Laboratory of Digestive Diseases, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, ChinaNon-alcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide, and is closely associated with the increased risk of the prevalence of obesity and diabetes. NAFLD begins with the presence of >5% excessive lipid accumulation in the liver, and potentially develops into non-alcoholic steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma. Therefore, insight into the pathogenesis of NAFLD is of key importance to its effective treatment. Iron is an essential element in the life of all mammalian organisms. However, the free iron deposition is positively associated with histological severity in NAFLD patients due to the production of reactive oxygen species via the Fenton reaction. Recently, several iron metabolism-targeted therapies, such as phlebotomy, iron chelators, nanotherapeutics. and ferroptosis, have shown their potential as a therapeutic option in the treatment of NAFLD and as a clinical strategy to intervene in the progression of NAFLD. Herein, we review the recent overall evidence on iron metabolism and provide the mechanism of hepatic iron overload-induced liver pathologies and the recent advances in iron metabolism-targeted therapeutics in the treatment of NAFLD.http://www.sciencedirect.com/science/article/pii/S2542568422000459Non-alcoholic fatty liver disease (NAFLD)Hepatic iron overloadPhlebotomyIron chelatorsNanomedicineFerroptosis
spellingShingle Hanqing Chen
Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target
Liver Research
Non-alcoholic fatty liver disease (NAFLD)
Hepatic iron overload
Phlebotomy
Iron chelators
Nanomedicine
Ferroptosis
title Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target
title_full Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target
title_fullStr Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target
title_full_unstemmed Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target
title_short Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target
title_sort iron metabolism in non alcoholic fatty liver disease a promising therapeutic target
topic Non-alcoholic fatty liver disease (NAFLD)
Hepatic iron overload
Phlebotomy
Iron chelators
Nanomedicine
Ferroptosis
url http://www.sciencedirect.com/science/article/pii/S2542568422000459
work_keys_str_mv AT hanqingchen ironmetabolisminnonalcoholicfattyliverdiseaseapromisingtherapeutictarget